Department of Surgery, Yokohama City University, Yokohama, Japan
Department of Surgery, Yokohama City University, Yokohama, Japan.
Anticancer Res. 2024 Nov;44(11):5035-5041. doi: 10.21873/anticanres.17327.
BACKGROUND/AIM: The systemic immune-inflammation index (SII) is a calculated biomarker developed to predict the prognosis of malignant tumors. This study evaluated the influence of the SII in patients with esophageal cancer (EC) who underwent curative resection.
Patients who underwent radical esophagectomy and lymph node dissection for EC were enrolled. The SII was calculated as follows: neutrophil count (cell/mm) × platelet count (cell/mm ×10)/lymphocyte count (cell/mm). The SII, patient characteristics, overall survival (OS), and recurrence-free survival (RFS) were assessed.
A total of 180 patients were included in this study. The cutoff value of the SII was set at 500 according to previous studies. Of the 180 patients, 100 were classified into the SII-high group and 80 into the SII-low group. The 3- and 5-year OS rates were 59.0% and 54.0%, respectively, in the SII-high group and 80.0% and 75.0%, respectively, in the SII-low group, showing significant differences between the groups (p=0.001). A multivariate analysis for the OS demonstrated that the SII was an independent prognostic factor (hazard ratio=2.333, 95% confidence interval=1.411-3.860, p<0.001), with similar results obtained for the RFS. Furthermore, hematological recurrence was significantly higher in the SII-high group than in the SII-low group (36.0% vs. 17.5%, p=0.006).
The preoperative SII was an independent prognostic factor for OS and RFS in patients with EC who underwent curative resection. Thus, the SII can be a useful marker for the treatment and management of EC.
背景/目的：全身性免疫炎症指数（SII）是一种计算生物标志物，用于预测恶性肿瘤的预后。本研究评估了 SII 对接受根治性切除术的食管癌（EC）患者的影响。
纳入接受根治性食管切除术和淋巴结清扫术的 EC 患者。SII 计算如下：中性粒细胞计数（细胞/mm）×血小板计数（细胞/mm×10）/淋巴细胞计数（细胞/mm）。评估 SII、患者特征、总生存期（OS）和无复发生存期（RFS）。
本研究共纳入 180 例患者。根据既往研究，将 SII 的截止值设定为 500。在 180 例患者中，100 例分为 SII 高组，80 例分为 SII 低组。SII 高组的 3 年和 5 年 OS 率分别为 59.0%和 54.0%，SII 低组分别为 80.0%和 75.0%，两组之间差异有统计学意义（p=0.001）。OS 的多因素分析表明，SII 是独立的预后因素（危险比=2.333，95%置信区间=1.411-3.860，p<0.001），RFS 也有类似结果。此外，SII 高组的血液学复发率明显高于 SII 低组（36.0%比 17.5%，p=0.006）。
术前 SII 是接受根治性切除术的 EC 患者 OS 和 RFS 的独立预后因素。因此，SII 可以作为 EC 治疗和管理的有用标志物。
